Expression Of TROP2 And VEGFR2,and Their Correlation With Clinicopathological Factors In Triple Negative Breast Cancer

Breast cancer is one of the most serious malignant tumors to women's health in the world.in recent years,the incidence of breast cancer is on the rise year by year,and has become the highest incidence of female malignant tumors,the onset age of patients also has a younger trend.Therefore,breast cancer has been the focus and focus of research all over the world.In our country,the incidence trend of breast cancer is consistent with that of global breast cancer,and the patients are also younger,the recurrence rate and fatality rate are rising,which seriously endangers the health status of women in our country.According to estrogen receptor(ER),progesterone receptor(PR)The expression of human epidermal growth factor receptor(HER2)in human epidermal growth factor receptor(HER2)can be classified as non-triple-negative breast cancer and triple-negative breast cancer.Features.At present,it is generally believed that the onset age of patients with three negative breast cancer is earlier than that of other types of breast cancer,the invasiveness of tumor is stronger,the possibility of recurrence and metastasis is greater,and the prognosis is often worse.At the present stage,surgical resection is the first choice for the main treatment of TNBC,and chemotherapy and radiotherapy are the auxiliary methods after operation.However,based on the special biological behavior of TNBC,chemotherapy and radiotherapy often have little effect.Nowadays,molecular targeted therapy has been widely used in tumor therapy,and there is still no ideal moleculartarget for TNBC patients.Therefore,the ideal molecular target for TNBC is There is an urgent need to address the issue.Human trophoblast cell surface antigen 2(TROP2),which is derived from the surface of trophoblast cell in human embryonic period,is normally expressed during human embryonic period,but is not expressed or expressed in normal tissues of human.TROP2 is also known as a tumor-related calcium signal transconductor 2(TACSTD2),and is a regulatory protein of a cell surface calcium signal,Intracellular calcium signal transduction is regulated.Recent studies have shown that TROP2 is highly expressed in many human malignant tumors,such as liver cancer,colorectal cancer,gastric cancer,ovarian cancer and prostate cancer,which can promote the proliferation and metastasis of tumor cells.However,there is no report on the expression of TROP2 in TNBC and its effect on prognosis.Vascular endothelial growth factor receptor 2(VEGFR2)is the receptor of vascular endothelial growth factor(VEGF),which is a member of vascular endothelial growth factor receptor family.The occurrence of solid tumors usually begins with neovascularization,and solid tumors often suggest rich vascular distribution in imaging.The family of vascular endothelial growth factor can not be occupied in angiogenesis.Or lack of an important position.Studies have shown that VEGFR2 plays an important role in tumor angiogenic regulation.It is highly expressed in a variety of human malignant solid tumors,but it is low in normal human tissues.In view of the lack of molecular targets for immunotargeted therapy of TNBC,the expression of TROP2 and VEGFR2 in triple negative breast cancer and its relationship with clinicopathological factors and prognosis were observed by immunohistochemical method in order to find a new molecular target for immunotargeted therapy of triple negative breast cancer.Research methods:1.From 2009 to 2014,288 patients with breast cancer were selected from Jiangsu Cancer Hospital,including 151 cases of triple negative breast cancer and 137 cases of non triple negative breast cancer.The patient was 35-77 years old,with an average age of 54 years.All patients did not receive radiotherapy,chemotherapy and immunotherapy before operation.The clinicopathological data of the patients included in the study included age,histology grade,clinical stage,tumor size,lymph node metastasis and distant metastasis,and survival follow-up information was collected within 5 to 10 years.OS was the time from diagnosis to death,and the disease was at the last follow-up.The survival of human beings is included in the statistics.Another 48 cases of benign breast tumors and 48 cases of normal breast tissues were selected as control group.2.Observe HE staining section,select typical lesion site,mark well,make breast cancer tissue chip,specification is 6 � 10 matrix with aperture 2mm.3.The expression of TROP2 and VEGFR2 in triple negative breast cancer,non-triple negative breast cancer,benign breast tumor and normal breast tissue was detected by Envision two-step method.The relationship between TROP2 and VEGFR2 and clinicopathological factors and prognosis of triple negative breast cancer was analyzed.The results:The expression of TROP2 and VEGFR2 in 151 cases of triple negative breast cancer,137 cases of non-triple negative breast cancer,48 cases of benign breast tumor and 48 cases of normal breast tissue were detected by immunohistochemistry.The results showed that the positive expression rate of TROP2 was 70.19%(106 /151)in three negative breast cancer,54.74%(75/137)in non-three negative breast cancer,18.75%(9/48)in benign breast tumor and 12.5%(6/48)in normal breast tissue.TROP2 was three negative in breast cancer.The positive expression rate of VEGFR2 in breast cancer was higher than that in non-triple negative breast cancer,benign breast tumor and normal breast tissue(P < 0.05).The positive expression rate of breast cancer in three negative breast cancer was 45.03%(68/151),which was significantly higher than that in non-triple negative breast cancer(32.85%),benign breast tumor(27.08%,13/48)and normal breast tissue(25.00%,12/48).The co-positive expression rate of TROP2 and VEGFR2 in three negative breast cancer was 30.46%(46/151).It was significantly higher than that of non-triple negative breast cancer(21.17%,29/137),benign breast tumor(10.42%,5/48)and normal breast tissue(8.33%,4/48)(P < 0.05).The positive expression of TROP2 and VEGFR2 in triple negative breast cancer and the clinical data of the patients were analyzed.the results showed that the high expression of TROP2 and VEGFR2 protein in three negative breast cancer tissues was correlated with the histological grade,clinical stage and distant metastasis of triple negative breast cancer,but not with age,mass size,menopausal or not,and lymph node metastasis.The positive expression of TROP2 in triple negative breast cancer was correlated with histologic grade,clinical stage,lymph node metastasis and distant metastasis of triple negative breast cancer.Positive expression of VEGFR2 There was a correlation with distant metastasis.Univariate regression analysis showed that the poor survival prognosis of patients with triple negative breast cancer was correlated with the co-positive expression of TROP2 and VEGFR2 protein,tumor size,clinical stage and distant metastasis.Multivariate regression analysis showed that TROP2 and VEGFR2 were co-positive,clinical stage and distant metastasis were independent prognostic factors for triple negative breast cancer.The survival time of patients with three negative breast cancer with high expression of TROP2 and VEGFR2 at the same time wasanalyzed.it was found that the overall survival time of patients with high expression of TROP2 and VEGFR2 protein was significantly lower than that of patients with TRO.The overall survival time of patients with low or no expression of P2 and VEGFR2 proteins at the same time.Conclusion:1.The co-expression of TROP2 and VEGFR2 in triple negative breast cancer can be used as an independent prognostic factor for triple negative breast cancer.TROP2 and VEGFR2 can be used as new molecular targets for triple negative breast cancer.2.TROP2 and VEGFR2 are expected to be used in prognosis evaluation and immunotargeted therapy of triple negative breast cancer.